Insider Selling: Tarsus Pharmaceuticals (NASDAQ:TARS) Director Sells $979,750.00 in Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Director William Phd Link sold 12,500 shares of the firm’s stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $78.38, for a total value of $979,750.00. Following the completion of the sale, the director directly owned 94,487 shares in the company, valued at approximately $7,405,891.06. The trade was a 11.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tarsus Pharmaceuticals Price Performance

Shares of Tarsus Pharmaceuticals stock traded up $1.42 on Thursday, reaching $79.06. The company’s stock had a trading volume of 426,958 shares, compared to its average volume of 748,133. The company has a quick ratio of 3.17, a current ratio of 3.20 and a debt-to-equity ratio of 0.21. The company has a market capitalization of $3.47 billion, a P/E ratio of -72.53 and a beta of 0.54. The stock has a 50-day moving average price of $68.73 and a 200-day moving average price of $66.71. Tarsus Pharmaceuticals, Inc. has a 52-week low of $51.57 and a 52-week high of $91.53.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its earnings results on Thursday, August 6th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.24). Tarsus Pharmaceuticals had a negative net margin of 7.67% and a negative return on equity of 13.53%. The business had revenue of $173.91 million for the quarter, compared to analysts’ expectations of $169.65 million. Analysts expect that Tarsus Pharmaceuticals, Inc. will post -2.4 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have issued reports on TARS shares. Jefferies Financial Group increased their price objective on shares of Tarsus Pharmaceuticals from $88.00 to $105.00 and gave the company a “buy” rating in a report on Tuesday, September 8th. Oppenheimer upped their price target on shares of Tarsus Pharmaceuticals from $97.00 to $100.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 12th. Guggenheim lowered their price objective on Tarsus Pharmaceuticals from $90.00 to $89.00 and set a “buy” rating on the stock in a report on Tuesday, July 21st. Mizuho cut their price objective on Tarsus Pharmaceuticals from $100.00 to $98.00 and set an “outperform” rating for the company in a research note on Friday, July 31st. Finally, Wall Street Zen cut Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $94.00.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

A number of institutional investors have recently bought and sold shares of TARS. Rockefeller Capital Management L.P. grew its stake in shares of Tarsus Pharmaceuticals by 15.5% in the 4th quarter. Rockefeller Capital Management L.P. now owns 1,283 shares of the company’s stock valued at $105,000 after buying an additional 172 shares during the period. Parallel Advisors LLC raised its position in shares of Tarsus Pharmaceuticals by 139.2% during the 1st quarter. Parallel Advisors LLC now owns 500 shares of the company’s stock valued at $35,000 after buying an additional 291 shares during the period. Strs Ohio raised its position in shares of Tarsus Pharmaceuticals by 4.8% during the 1st quarter. Strs Ohio now owns 8,800 shares of the company’s stock valued at $617,000 after buying an additional 400 shares during the period. Swiss National Bank lifted its holdings in Tarsus Pharmaceuticals by 0.8% in the first quarter. Swiss National Bank now owns 62,933 shares of the company’s stock valued at $4,415,000 after acquiring an additional 500 shares during the last quarter. Finally, PNC Financial Services Group Inc. lifted its holdings in Tarsus Pharmaceuticals by 367.1% in the first quarter. PNC Financial Services Group Inc. now owns 710 shares of the company’s stock valued at $50,000 after acquiring an additional 558 shares during the last quarter. 90.01% of the stock is owned by hedge funds and other institutional investors.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a commercial-stage ophthalmic pharmaceutical company focused on developing and marketing treatments for eye conditions with significant unmet medical needs. The company’s lead product is XDEMVY (lotilaner ophthalmic solution) 0.25%, a prescription eye drop approved by the U.S. Food and Drug Administration in 2023 for the treatment of Demodex blepharitis, a common eyelid disorder associated with an infestation of Demodex mites.

XDEMVY is designed to target and eliminate Demodex mites, addressing an underlying cause of the disease rather than only managing its symptoms.